CHMP gives green light to three new medicines

Three new medicines have been recommended for approval by the Committee for Medical Products for Human Use (CHMP) in the past month.  The first recommended was Opsumit, an orphan medicine intended for the treatment of pulmonary arterial hypertension in adults. Following this the committee gave a positive recommendation for Brintellix in the treatment of major depressive episodes in adults. Finally, the generic medicine Levetiracetam Hospira also received a positive opinion for use in epilepsy. Regarding epilepsy, the CHMP also recommended switching the marketing authorisation for the orphan medicine Diacomit from a conditional to a full approval. Diacomit is used in